David Morris, MD, FACS, discusses how PSMA PET imaging may impact targeted therapies for prostate cancer in the future.
David Morris, MD, FACS, a urologist at Tennessee Urology Associates, discusses how PSMA PET imaging may impact targeted therapies for prostate cancer in the future.
0:08 | PSMA/PET imaging has really exploded in the last year. It's certainly something we've been aware of clinically for several years from Europe or Australia that's been highly used. And we've kind of viewed it with jealousy from the US market. It has not been available; it's not been covered.
0:23 | And as you would expect, the new technology is immediately blossomed where you can obtain it. It's something that's quickly supplanting conventional imaging which was just not as ideal as we would hope for in terms of sensitivity. So as the PSM a market for access has grown, the coverage has actually been better than we anticipated when it first launched. And I think we all recognize it's better than conventional imaging in terms of finding metastatic lesions and with that and enables us to grow our potential patient base for targeted therapy. So, to tell someone that they have metastatic disease earlier or be able to start them on a targeted therapy earlier, and certainly beneficial versus the wait and watch with conventional imaging until they have metastasis detected.